Montelukast Intermediate MK5

Nengte Technology Co., Ltd. is a wholly-owned subsidiary of the listed company Guanfu Co., Ltd. (Stock Code: 002102). It was established in 2006 with a registered capital of 220 million yuan. At present, there are three production plants, covering an area of 840 mu. The company has total assets of nearly 1.8 billion yuan, sales revenue of 950 million yuan in 2017, more than 1000 employees and more than 100 technicians. It is a high-tech enterprise mainly engaged in the production, research and development, sales of pharmaceutical intermediates and fine chemical products. At present, the company has two product series. The first is a series of pharmaceutical intermediates, with montelukast sodium intermediates for asthma and anti allergy and rosuvastatin intermediates for hyperlipidemia and hypercholesterolemia as leading products; The second is vitamin E and its intermediates as a starting point for the development of vitamin series. Our company has gradually established a quality management system in accordance with GMP standards, and has passed ISO9001:2008 certification, PMDA certification, USFDA certification (No. 303521), and fami-qs certification. The company will develop its leading products into products with global production capacity, market share and leading quality, forming the core competitiveness of the enterprise, and will be able to build a 10 billion strong enterprise.